NEW YORK – Rare disease diagnostics and research firm Centogene said on Thursday that it plans to sell a total of 3.5 million common shares in a primary and secondary public stock offering.
The offering consists of 2 million common shares offered by the company and 1.5 million common shares offered by selling shareholders at a price of $14 per share, for gross proceeds of $28 million and $21 million, respectively. Centogene will not receive any proceeds from the sale by the selling shareholders.